Published in Alzheimers Dement on November 01, 2009
Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One (2011) 2.30
Healthy aging and disease: role for telomere biology? Clin Sci (Lond) (2011) 2.10
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Neighborhood disorder and telomeres: connecting children's exposure to community level stress and cellular response. Soc Sci Med (2013) 1.51
Stress, Meditation, and Alzheimer's Disease Prevention: Where The Evidence Stands. J Alzheimers Dis (2015) 1.50
A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res (2010) 1.30
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res (2015) 1.17
Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev (2015) 1.05
Telomere length is age-dependent and reduced in monocytes of Alzheimer patients. Exp Gerontol (2011) 1.05
Telomere shortening in neurological disorders: an abundance of unanswered questions. Trends Neurosci (2014) 0.96
Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. Mol Psychiatry (2014) 0.94
Leukocyte telomere length and age at menopause. Epidemiology (2014) 0.87
Shorter telomere length in peripheral blood leukocytes is associated with childhood autism. Sci Rep (2014) 0.85
Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. Int J Alzheimers Dis (2012) 0.81
Meta-analysis of Telomere Length in Alzheimer's Disease. J Gerontol A Biol Sci Med Sci (2016) 0.81
The Telomere/Telomerase System in Chronic Inflammatory Diseases. Cause or Effect? Genes (Basel) (2016) 0.79
Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis (2011) 0.78
Enhanced microglial pro-inflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening. Aging Cell (2015) 0.78
Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms. Front Psychiatry (2014) 0.77
High sodium intake is associated with short leukocyte telomere length in overweight and obese adolescents. Int J Obes (Lond) (2015) 0.76
Leukocyte telomere length and hippocampus volume: a meta-analysis. F1000Res (2015) 0.75
Influence of Amalaki Rasayana on telomerase activity and telomere length in human blood mononuclear cells. J Ayurveda Integr Med (2017) 0.75
Leukocyte telomere length is linked to vascular risk factors not to Alzheimer's disease in the VITA study. J Neural Transm (Vienna) (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Telomere measurement by quantitative PCR. Nucleic Acids Res (2002) 18.69
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell (2005) 12.73
Association between telomere length in blood and mortality in people aged 60 years or older. Lancet (2003) 10.56
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
Cellular senescence in aging primates. Science (2006) 6.24
Telomeres and aging. Physiol Rev (2008) 4.79
Alzheimer's disease and angiogenesis. Lancet (2003) 4.19
Senescence induced by altered telomere state, not telomere loss. Science (2002) 4.17
Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation (2002) 4.12
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Alzheimer's disease and Parkinson's disease. N Engl J Med (2003) 3.88
Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A (2007) 3.67
Beginning to understand the end of the chromosome. Cell (2004) 3.46
Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci (2004) 3.13
Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet (2004) 2.83
Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging (2002) 2.46
Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab Invest (2000) 2.42
Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A (1995) 2.40
Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. Ann Neurol (2006) 2.21
Telomere lengths are characteristic in each human individual. Exp Gerontol (2002) 2.13
The epidemiology of human telomeres: faults and promises. J Gerontol A Biol Sci Med Sci (2008) 2.11
Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. Mol Cell Biol (2004) 1.99
Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol (1989) 1.95
Telomere dysfunction as a cause of genomic instability in Werner syndrome. Proc Natl Acad Sci U S A (2007) 1.80
Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease. Mech Ageing Dev (2008) 1.69
Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol (2005) 1.64
Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol (2004) 1.57
Telomere instability in the male germline. Hum Mol Genet (2005) 1.55
Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke (2003) 1.42
Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol (2005) 1.19
Aging, telomeres, and atherosclerosis. Cardiovasc Res (2005) 1.17
Telomere biology and cellular aging in nonhuman primate cells. Exp Cell Res (2002) 1.14
Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci (2002) 1.14
Vascular factors in dementia: an overview. J Neurol Sci (2004) 1.12
Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res (1999) 1.09
Telomeres shorten with age in rat cerebellum and cortex in vivo. J Anti Aging Med (2003) 1.04
Telomere shortening in T lymphocytes of older individuals with Down syndrome and dementia. Neurobiol Aging (2005) 1.01
Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiol Aging (1994) 0.99
Dyskeratosis congenita and telomerase. Curr Opin Pediatr (2004) 0.98
Telomeric DNA length in cerebral gray and white matter is associated with longevity in individuals aged 70 years or older. Exp Gerontol (2007) 0.93
The extent and significance of telomere loss with age. Ann N Y Acad Sci (2004) 0.91
Telomerase induction in astrocytes of Sprague-Dawley rat after ischemic brain injury. Neurosci Lett (2004) 0.88
Seizures and tissue injury induce telomerase in hippocampal microglial cells. Exp Neurol (2002) 0.86
Effects of axotomy on telomere length, telomerase activity, and protein in activated microglia. J Neurosci Res (2005) 0.83
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA (2005) 6.23
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature (2009) 3.83
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol (2008) 2.28
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Diagnostic evaluation of elderly patients with mild memory problems. Ann Intern Med (2003) 2.15
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. Cancer (2014) 2.12
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. Mol Cell Biol (2004) 1.99
Genomic distribution and functional analyses of potential G-quadruplex-forming sequences in Saccharomyces cerevisiae. Nucleic Acids Res (2007) 1.98
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol (2007) 1.91
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med (2006) 1.85
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Monoaminergic orchestration of motor programs in a complex C. elegans behavior. PLoS Biol (2013) 1.69
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain (2013) 1.64
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol (2007) 1.60
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci (2012) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol (2007) 1.57
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol (2007) 1.57
Cdc13 OB2 dimerization required for productive Stn1 binding and efficient telomere maintenance. Structure (2012) 1.56
Detection of G-quadruplex DNA in mammalian cells. Nucleic Acids Res (2013) 1.53
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain (2012) 1.47
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol (2007) 1.45
Altered gene expression in the Werner and Bloom syndromes is associated with sequences having G-quadruplex forming potential. Nucleic Acids Res (2009) 1.44
Nuclear factor {kappa}B-mediated transactivation of telomerase prevents intimal smooth muscle cell from replicative senescence during vascular repair. Arterioscler Thromb Vasc Biol (2010) 1.44
Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med (2007) 1.43
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol (2012) 1.42
Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement (2011) 1.41
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol (2010) 1.39
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
A comparison of multiple urine markers for interstitial cystitis. J Urol (2002) 1.37
Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis. Neuropsychology (2009) 1.35
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement (2006) 1.34
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One (2011) 1.32
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med (2005) 1.30
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment. J Virol (2009) 1.29
Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosis. Aging Cell (2007) 1.29
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol (2005) 1.23
Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med (2006) 1.22
Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 1.22
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol (2013) 1.22
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord (2011) 1.19
A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Stat Med (2004) 1.18
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol (2005) 1.18
Physiological origin of low-frequency drift in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). Magn Reson Med (2009) 1.17
Rudimentary G-quadruplex-based telomere capping in Saccharomyces cerevisiae. Nat Struct Mol Biol (2011) 1.14
Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement (2010) 1.14
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. Arch Neurol (2009) 1.13
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integr Cancer Ther (2009) 1.13
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.13